Browsing Tag
RENAL
1 post
CSL commits US$355m to lixudebart as rare kidney pipeline gains strategic weight
CSL is committing US$355 million upfront and funding a multi-indication clinical programme around Alentis Therapeutics’ lixudebart, giving the Australian biopharma group a potential new nephrology anchor as its existing Vifor portfolio faces material revenue headwinds.